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Biological systems, in most cases, recognize a pair of enantiomers as different substances eliciting
different responses. Therefore, one enantiomer may act as a very effective therapeutic agent whereas
the other enantiomer, at worst, interacts with a totally different target resulting in undesired side effects.
Thalidomide offers a tragic example that led to the death of approximately 2000 children and serious
malformation of arms and legs in 10,000 babies born around the world [1]. This disaster emphasized
the need for a greater regulation governing the use of drugs, particularly enantiomers. The impetus is
on synthetic chemists to provide highly efficient and reliable methods to access the desired compounds
in an enantiomerically pure format, avoiding underside effects of unwanted enantiomers. Regulatory
guidance was published, firstly in the US followed by the EU [2,3], reflecting rigorous steps required
to follow before an approval of racemates is granted. The Australian and Canadian guidance are
also based on similar principles [4,5]. As chiral drugs comprise more than half the drugs approved
worldwide, including many of the top-selling drugs [6], these regulations create a chronic problem for
the pharmaceutical industry. In particular, the costs associated with chiral separation of racemates.
Among the different approaches used to access enantiomerically pure compounds, chiral transition
metal complexes [7,8] and organocatalysts [9,10] evolved as essential instruments in the toolbox of
organic chemists. Their use has become a truly indispensable technology for industrial scale production
of active pharmaceutical ingredients [10,11]. This power emerges from their high efficiency to catalyze
a broad range of chemical transformations with high tolerance of numerous functional groups and
impressive levels of chemo-, regio-, diastereo-, and enantioselectivities. They have also facilitated the
discovery of new patterns of reactivity that by far opened the door to the creation of bonds forming
strategies that never existed previously.
This Special Issue includes four articles and one review.
The article by Qin et al. [12] provides computational DFT investigations on the bisphospholanoethane
(BPE)-ligated Cu-catalyzed enantioselective addition of enynes to ketones. Two BPE-mesitylcopper
(CuMes) catalysts, namely BPE-CuMes and (S,S)-Ph-BPE–CuMes, were employed to probe the reaction
mechanism with the emphasis on stereoselectivity. The calculations on the BPE-CuMes system indicated
that the active metallized enyne intermediate acts as the catalyst for the catalytic cycle.
The article by Adly, Ghanem and co-workers [13] contributes to the understanding of the
stereoselectivity of chiral dirhodium(II) carboxylate catalysts carrying N-protected tert-leucine ligand
through investigating the possible effect of ligand stereo-purity on catalyst structure and enantioselectivity.
This was also justified through a new X-ray crystal structure for the Rh2(S,S,S,R-PTTL)4 catalyst.
The article by Liu et al. [14] provides a concise method for the preparation of new C2-symmetric
six-membered NHCs and their application for the asymmetric diethylzinc addition of arylaldehydes.
The article by Rafin´ski [15] provides a highly efficient and enantioselective approach to the
synthesis of functionalized benzofuran-3(2H)-ones which proceeds via an intramolecular Stetter
reaction using β,β-disubstituted Michael acceptors in the construction of five-membered rings with
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fully-substituted quaternary stereogenic centers. As a result, a series of chiral 2,2-disubstituted
benzofuran-3(2H)-one derivatives with linear, branched, and cyclic aliphatic substitutions on the
quaternary stereogenic center were obtained in high yields and with excellent enantioselectivities of
up to 99% ee.
The review by Adly [16] provides an update on how the knowledge around the structure of
dirhodium(II) carboxylate catalysts has evolved over the years with a particular emphasis on the
impact of this knowledge on enantioselectivity prediction and catalyst design.
In conclusion, these five publications give an overview of the possibilities of different catalysts to be
used in different asymmetric transformations, in particular in synthetic reactions at very mild reaction
conditions. Finally, we sincerely thank all authors for their enthusiastic support and contributions
towards the success of this Special Issue.
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